title: Effects of administration of 17beta-oestradiol on serum leptin levels in healthy postmenopausal women.
abstract: OBJECTIVE
  Women have higher leptin levels than men at a certain degree of adiposity. The role of oestrogens in the regulation of serum leptin levels remains inconclusive. The aim of the present study was to investigate the effect of unopposed oestrogen replacement therapy, during two months, on serum leptin levels in postmenopausal women.
  
  
  METHODS
  A double-blind, placebo-controlled, randomized study.
  
  
  METHODS
  Twenty-five healthy postmenopausal women were studied (mean (+/- SD) age: 52.9 +/- 2.7 years, range of age: 48.7-57.4 years; mean body mass index (BMI): 26.4 +/- 4.2 kg/m2, range of BMI: 21.0-39.0 kg/m2). Twelve of these women were treated with 2 mg 17beta-oestradiol daily, and 13 postmenopausal women received placebo.
  
  
  METHODS
  Before and at the end of a 2-month study period, anthropometric and bio-electrical impedance measurements were performed, and fasting blood samples were taken, to determine serum levels of sex hormones and leptin.
  
  
  RESULTS
  During the 2-month study period, body weight had increased significantly in the placebo group compared with the treatment group, but no significant changes were observed in percentage of body fat or the amount of body fat in kg between the groups. Following administration of 17beta-estradiol, the median leptin level increased from 17.6 microg/l to 24.1 microg/l after 2 months (P = 0. 008 compared with baseline). This increase was significantly different from the placebo group (P = 0.019), which showed no change in circulating leptin levels.
  
  
  CONCLUSIONS
  This study demonstrates that unopposed oestrogen replacement therapy during 2 months in postmenopausal women slightly, but significantly, increases total serum leptin levels. This observation suggests a role for oestrogens in the regulation of leptin.
authors.affiliation: Department of Endocrinology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Elbers
authors.forename: G W
authors.initials: GW
authors.lastname: de Roo
authors.forename: C
authors.initials: C
authors.lastname: Popp-Snijders
authors.forename: A
authors.initials: A
authors.lastname: Nicolaas-Merkus
authors.forename: E
authors.initials: E
authors.lastname: Westerveen
authors.forename: B W
authors.initials: BW
authors.lastname: Joenje
authors.forename: J C
authors.initials: JC
authors.lastname: Netelenbos
mesh_terms: D001823:Body Composition; D015992:Body Mass Index; D004311:Double-Blind Method; D017097:Electric Impedance; D004958:Estradiol / Q000097:blood / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood*; D008875:Middle Aged; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D018709:Statistics, Nonparametric; D013739:Testosterone / Q000097:blood
chemical_list: D007328:Insulin; D020738:Leptin; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D004958:Estradiol